Referring Clinicians

Temporary Trial Recruitment Suspension due to the COVID-19 Pandemic

We are disappointed to announce that we will be temporarily suspending all new recruitment to all trials conducted at the Auckland Cancer Trials Center. We will be concentrating  our resources to provide the best possible care to patients who are already enrolled in trials and to contribute to local and national efforts of managing the current pandemic. Thank you for your patience.

    Trials Recruiting at ACTC 

    Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
    Multiple tumour streamGILEAD (GS-US-494-5484)A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the
    Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in
    Subjects with Advanced Solid Tumors
    GS-4224 (small molecule oral PDL1 Inhibitor)Advanced Solid Organ Malignancy with no further treatment options.

    TPS/CPS >10% in participants of the Biopsy Substudy
    Recruitment Open
    - Phase 1b Dose Escalation Cohort and Biopsy Substudy

    Expected to open in 2nd quarter 2020
    -Phase 2 Basket Dose Expansion Cohort: CPI Naïve -Melanoma, Renal, Urothelial, Gastric/GOJ, HNSCC,MSI High Cancer, Merkel Cell Carcinoma
    Melanoma (Advanced/ Metastatic) MK1308-001A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in
    Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
    MK1308 (CTLA4 Inhibitor) +/- PembrolizumabMetastatic Melanoma with disease progression after PD1 or PDL1 checkpoint inhibitor therapy

    Cohort F: MK1308+ pembrolizumab (6 weekly)
    Recruiting
    Upper Gastrointestinal (Advance) , Colorectal (Advance)CITRONReducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer PatientsmFOLFOX OR CAPOX +/- cimetidineFirst 2 cycles mFOLFOX + cimetidine or placebo assessing for acute neuropathy.Recruiting
    Colorectal (Metastatic)MedimmuneA phase 1/2 study of Durvalumab and Monalizumab in Adult Subjects with Select Advance Solid TumoursDurvalumab (antiPDL1) [D] +
    Monalizumab (anti CD94/NKG2A) [M] +
    Cetuximab (EGFR inhibitor) [C]
    Cohort C2 : RAS, BRAF wildtype, microsatelite stable, must have been exposed to 5FU/Oxali/Irinotecan/Bevacizumab in 1 or 2 lines of therapy. Randomised to either (D+M+C) or (M+C)Recruiting
    Merkel Cell CarcinomaMK-3475-913A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumoursPembrolizumab(antiPD1)Unresectable Stage III and Stage IV Merkel Cell Carcinoma( 1st line)Recruiting
    Prostate (mCRPC)MK-3475-365Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Pembrolizumab +Olaparib or Pembrolizumab +AbirateroneCohort A: (Pembro + Olaparib)- Must have received docetaxel +/- second chemo agent, up to 2 generation hormonal manipulations allowed (e.g. abiraterone, enzalutamide)

    Cohort D (Pembro + Abiraterone + Pred)- Chemo naïve for mCRPC (docetaxel allowed in mCNPC setting), no prior 2ng generation hormonal manipulation OR progressed on enzalutamide.
    Recruiting
    Melanoma, NSCLC, SCLCNP40435Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumoursPD1/TIM3 bi-specific antibody-Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma)
    -NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1%
    -SCLC: CPI-naive
    Recruiting
    Esophageal and Cervical SCCBP40234An Open Label Phase 2 Study Evaluating the activity of FAP-Interleukin2 Variant and Atezolizumab in advanced Solid Organ CancerAtezolizumab + FAP Interleukin2 Variant Second or subsequent line systemic therapy Recruiting

    How to Refer 

    Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

    Email us for any other inquiries: infoACTC@adhb.govt.nz

     

    Auckland Cancer Trials Centre

    Auckland City Hospital,

    2, Park Road, Grafton,

    1023, Auckland, New Zealand

    Patient Referrals 

    Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

    Email us for any other inquiries:

    infoACTC@adhb.govt.nz